Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

SPRY

ARS Pharmaceuticals Inc

Dec 13 • 04:00PM ET

11.90

Dollar change -0.74
Percentage change -5.85	%

Healthcare • Biotechnology • USA • NASD

Peers: ALNY IONS RNA ARWR SRPT NBIX ENTA VRTX RARE ASND

| Held by: VTI IWM VXF XBI IWO IBB VTWO SCHA VHT IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.51	Insider Own	47.60%	Shs Outstand	97.15M	Perf Week	-15.12%
Market Cap	1.09B	Forward P/E	-	EPS next Y	-0.36	Insider Trans	-11.34%	Shs Float	50.92M	Perf Month	-15.48%
Income	-49.10M	PEG	-	EPS next Q	-0.14	Inst Own	42.09%	Short Float	26.77%	Perf Quarter	-8.11%
Sales	2.57M	P/S	423.66	EPS this Y	-2.19%	Inst Trans	2.80%	Short Ratio	12.65	Perf Half Y	37.41%
Book/sh	2.07	P/B	5.75	EPS next Y	37.34%	ROA	-21.07%	Short Interest	13.63M	Perf Year	123.68%
Cash/sh	2.24	P/C	5.32	EPS next 5Y	-	ROE	-22.41%	52W Range	5.02 - 18.51	Perf YTD	117.15%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-1.44%	ROI	-24.43%	52W High	-35.71%	Beta	0.88
Dividend TTM	-	Quick Ratio	12.50	Sales past 5Y	-34.76%	Gross Margin	93.22%	52W Low	137.05%	ATR (14)	0.92
Dividend Ex-Date	-	Current Ratio	12.54	EPS Y/Y TTM	79.10%	Oper. Margin	-2356.15%	RSI (14)	34.70	Volatility	7.34% 6.42%
Employees	26	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-1912.15%	Recom	1.00	Target Price	29.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-26.75%	Payout	-	Rel Volume	0.91	Prev Close	12.64
Sales Surprise	259.65%	EPS Surprise	-40.35%	Sales Q/Q	-	Earnings	Nov 13 BMO	Avg Volume	1.08M	Price	11.90
SMA20	-12.52%	SMA50	-18.56%	SMA200	4.67%	Trades		Volume	984,617	Change	-5.85%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-20-24	Initiated	Cantor Fitzgerald	Overweight
Aug-13-24	Upgrade	Raymond James	Outperform → Strong Buy	$18 → $22
Aug-12-24	Reiterated	Leerink Partners	Outperform	$19 → $20
Jul-25-24	Initiated	Raymond James	Outperform	$18
Mar-05-24	Upgrade	Leerink Partners	Market Perform → Outperform	$6 → $18
Feb-20-24	Upgrade	William Blair	Mkt Perform → Outperform
Sep-20-23	Downgrade	William Blair	Outperform → Mkt Perform
Jan-31-23	Initiated	Wedbush	Outperform	$10
Jan-03-23	Initiated	William Blair	Outperform	$17
Dec-13-22	Initiated	SVB Leerink	Outperform	$14

Dec-12-24 02:32PM	ARS Pharmaceuticals Announces Filings for Approval of neffy in China, Japan and Australia (GlobeNewswire)
Dec-04-24 08:00AM	ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost (GlobeNewswire) +5.95%
Nov-14-24 02:08AM	ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ... (GuruFocus.com)
Nov-13-24 07:40AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -15.23%
06:30AM	ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
07:06AM	Loading…
Nov-12-24 07:06AM	ARS Pharmaceuticals announces agreement with ALK to commercialize neffy (TipRanks) -5.03%
Nov-11-24 04:02PM	ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray (Investor's Business Daily)
11:01AM	ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m (Pharmaceutical Technology)
07:41AM	ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 (Benzinga)
07:00AM	ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy in Europe, Canada and Other Geographies Outside the United States (GlobeNewswire)
Nov-09-24 05:30PM	ALK licenses rights to neffy , the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) (GlobeNewswire)
Nov-06-24 09:55AM	Wall Street Analysts Think ARS Pharmaceuticals, Inc. (SPRY) Could Surge 67.56%: Read This Before Placing a Bet (Zacks)
08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences (GlobeNewswire)
Oct-24-24 08:30AM	ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (GlobeNewswire)
Oct-14-24 09:55AM	Wall Street Analysts Believe ARS Pharmaceuticals, Inc. (SPRY) Could Rally 76.79%: Here's is How to Trade (Zacks)
10:33AM	Loading…
Sep-30-24 10:33AM	Neffy nasal spray: a game changer for asthma patients and epinephrine delivery? (Pharmaceutical Technology)
Sep-23-24 08:00AM	ARS Pharmaceuticals Announces U.S. Availability of neffy (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis (GlobeNewswire)
Sep-11-24 08:20AM	ARS Pharmaceuticals (SPRY): A Bull Case Theory (Insider Monkey)
Sep-10-24 04:05PM	ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-09-24 04:47PM	ARS Pharmaceuticals Submits sNDA to FDA for neffy 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.) (GlobeNewswire)
Sep-06-24 12:00PM	ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's Why (Zacks)
Sep-04-24 08:00AM	ARS Pharmaceuticals Launches Pre-Ordering Services for neffy to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis (GlobeNewswire)
Aug-27-24 10:08AM	Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned (UPDATED) (Benzinga) +5.76%
Aug-26-24 09:29AM	EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)
Aug-22-24 12:27AM	ARS Pharmaceuticals Inc (SPRY) CFO Kathleen Scott Sells 12,500 Shares (GuruFocus.com)
Aug-20-24 12:21PM	ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst (Benzinga)
Aug-15-24 07:02PM	Insider Sale: COO Brian Dorsey Sells 30,000 Shares of ARS Pharmaceuticals Inc (SPRY) (GuruFocus.com)
Aug-12-24 04:32AM	ARS Pharmaceuticals anaphylaxis nasal spray gains FDA approval (Pharmaceutical Technology)
Aug-09-24 01:34PM	FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment (Benzinga) +10.01%
12:49PM	ARS Pharmaceuticals Receives FDA Approval of neffy (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis (GlobeNewswire)
09:01AM	Loading…
Aug-07-24 09:01AM	ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Aug-06-24 05:20PM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:01PM	ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 10:01AM	ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jun-28-24 06:30AM	ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire) +5.71%
May-12-24 09:01PM	ARS Pharmaceuticals Inc (SPRY) Q1 2024 Earnings: Aligns with EPS Projections Amidst Regulatory ... (GuruFocus.com)
May-09-24 11:54PM	SPRY Stock Earnings: ARS Pharmaceuticals Meets EPS for Q1 2024 (InvestorPlace)
04:05PM	ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-30-24 09:01AM	ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand (GlobeNewswire)
Apr-05-24 06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-03-24 09:01AM	ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy (Epinephrine Nasal Spray) (GlobeNewswire)
Apr-01-24 12:00PM	ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should Know (Zacks) -7.34%
Mar-26-24 08:50AM	Recent Price Trend in ARS Pharmaceuticals, Inc. (SPRY) is Your Friend, Here's Why (Zacks) +9.53%
Mar-21-24 10:53PM	SPRY Stock Earnings: ARS Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
05:33PM	ARS Pharmaceuticals Inc (SPRY) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
04:05PM	ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-15-24 06:00AM	Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024 (InvestorPlace)
Mar-07-24 04:05PM	ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy Investor Day (GlobeNewswire)
Mar-06-24 09:01AM	ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire)
Feb-26-24 09:01AM	ARS Pharmaceuticals announces neffy meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study (GlobeNewswire)
Feb-22-24 09:01AM	ARS Pharmaceuticals to Host Virtual neffy Investor Day on March 7, 2024 (GlobeNewswire)
Feb-20-24 09:01AM	ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA's Complete Response Letter (GlobeNewswire)
Feb-05-24 09:01AM	ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy (epinephrine nasal spray) at 2024 AAAAI Annual Meeting (GlobeNewswire)
Nov-09-23 04:00PM	ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) +8.75%
11:02AM	ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis (GlobeNewswire)
Oct-06-23 09:03AM	ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy (epinephrine nasal spray) (GlobeNewswire) +7.02%
Oct-03-23 09:03AM	Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology (GlobeNewswire)
03:01AM	Chief Legal Officer Alexander Fitzpatrick Buys 86,258 Shares of ARS Pharmaceuticals Inc (GuruFocus.com)
Sep-29-23 07:50PM	ARS Pharmaceuticals, Harmonic, and More Stocks See Action From Activist Investors (Barrons.com)
01:39PM	Hedge Fund and Insider Trading News: Dan Loeb, Crispin Odey, Ray Dalio, D. E. Shaw, Eisler Capital, Glazer Capital, Gatos Silver Inc (GATO), ARS Pharmaceuticals Inc (SPRY), and More (Insider Monkey)
10:00AM	Small Biotech Stocks Haven't Shined of Late, but I Think These 3 Could Be Stars (TheStreet.com)
10:00AM	3 Small Biotech Stocks That Could Be Stars (TheStreet.com)
Sep-21-23 12:28PM	ARS Pharmaceuticals (SPRY) Down on CRL for Nasal Spray (Zacks) +25.68%
10:43AM	Biotech Stock Roundup: GSK's Drug Approval, MRNA's Vaccine News, PTCT & SPRY Down (Zacks)
06:28AM	Feds Message Is Louder Than Its Rate Call. Why Thats Critical for Investors. (Barrons.com)
Sep-20-23 12:42PM	Why Shares of ARS Pharmaceuticals Are Plummeting on Wednesday (Motley Fool) -55.79%
10:31AM	FDA says it needs more research before deciding to approve nasal spray to treat dangerous allergies (AP Finance)
10:26AM	FDAs Surprise Rejection of No-Shot Alternative to EpiPen Halves Shares of ARS Pharma (Barrons.com)
09:49AM	FDA Declines to Approve Epinephrine Nasal Spray, Asks for Additional Data (The Wall Street Journal)
06:13AM	ARS Pharma shares plummet after FDA asks for extra test of nasal spray (Investing.com)
Sep-19-23 10:49PM	FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study (GlobeNewswire) -11.22%
Sep-08-23 07:10PM	Imperial Petroleum, ARS Pharmaceuticals Stock, and More See Action From Activist Investors (Barrons.com)
Aug-10-23 04:00PM	ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Jun-20-23 08:00AM	ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis (GlobeNewswire)
May-15-23 02:11PM	ARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal Spray (Zacks)
09:00AM	ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-12-23 11:51AM	Why ARS Pharmaceuticals Stock Is Soaring Today (Benzinga) +77.88%
May-11-23 07:01PM	FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis (GlobeNewswire)
May-09-23 09:10AM	ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis (GlobeNewswire) -14.31%
Apr-21-23 10:05AM	Companies Like ARS Pharmaceuticals (NASDAQ:SPRY) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-28-23 09:39AM	ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis (GlobeNewswire)
Mar-25-23 09:10AM	ARS Pharmaceuticals Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Mar-23-23 04:01PM	ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-22-23 06:19AM	One ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider upped their stake in the previous year (Simply Wall St.) -5.56%
Feb-23-23 04:01PM	ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors (GlobeNewswire)
Feb-22-23 04:05PM	ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis (GlobeNewswire)
Feb-09-23 06:30AM	ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023 (GlobeNewswire) +5.76%
05:43AM	Insiders own 34% of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) shares but individual investors control 36% of the company (Simply Wall St.)
Nov-10-22 08:00AM	ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis (GlobeNewswire)

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chakma Justin	Chief Business Officer	Dec 12 '24	Option Exercise	0.84	117,333	98,560	253,713	Dec 13 07:53 PM
Chakma Justin	Chief Business Officer	Dec 13 '24	Option Exercise	1.44	27,272	39,272	163,652	Dec 13 07:53 PM
Chakma Justin	Chief Business Officer	Dec 12 '24	Sale	12.27	117,333	1,439,124	136,380	Dec 13 07:53 PM
Chakma Justin	Chief Business Officer	Dec 13 '24	Sale	12.06	27,272	328,968	136,380	Dec 13 07:53 PM
Dorsey Brian	Chief Operating Officer	Dec 12 '24	Option Exercise	0.64	25,000	16,000	31,024	Dec 13 07:52 PM
Dorsey Brian	Chief Operating Officer	Dec 11 '24	Option Exercise	0.64	15,000	9,600	21,024	Dec 13 07:52 PM
Dorsey Brian	Chief Operating Officer	Dec 12 '24	Sale	12.30	25,000	307,432	6,024	Dec 13 07:52 PM
Dorsey Brian	Chief Operating Officer	Dec 11 '24	Sale	12.43	15,000	186,426	6,024	Dec 13 07:52 PM
Chakma Justin	Officer	Dec 13 '24	Proposed Sale	12.06	27,272	328,967		Dec 13 05:24 PM
Chakma Justin	Chief Business Officer	Dec 10 '24	Option Exercise	0.84	50,000	42,000	186,380	Dec 12 05:41 PM
Chakma Justin	Chief Business Officer	Dec 10 '24	Sale	13.15	50,000	657,625	136,380	Dec 12 05:41 PM
Chakma Justin	Officer	Dec 10 '24	Proposed Sale	11.50	117,333	1,349,330		Dec 12 05:02 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Dec 10 '24	Sale	13.16	100,000	1,316,420	1,148,499	Dec 11 06:30 PM
Lowenthal Richard E	PRESIDENT AND CEO	Dec 10 '24	Sale	13.16	100,000	1,316,420	1,148,499	Dec 11 06:30 PM
Dorsey Brian	Officer	Dec 11 '24	Proposed Sale	13.31	61,200	814,572		Dec 11 05:31 PM
Chakma Justin	Director	Dec 10 '24	Proposed Sale	14.02	50,000	701,000		Dec 10 04:48 PM
Lowenthal Richard E	Officer	Dec 10 '24	Proposed Sale	13.40	300,000	4,020,000		Dec 10 11:15 AM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Dec 06 '24	Option Exercise	4.67	25,665	119,852	3,433,512	Dec 09 05:43 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Dec 06 '24	Option Exercise	8.42	11,876	99,996	4,327,189	Dec 09 05:43 PM
Lowenthal Richard E	PRESIDENT AND CEO	Dec 06 '24	Option Exercise	4.67	25,665	119,852	3,433,512	Dec 09 05:25 PM
Lowenthal Richard E	PRESIDENT AND CEO	Dec 06 '24	Option Exercise	8.42	11,876	99,996	4,327,189	Dec 09 05:25 PM
Chakma Justin	Chief Business Officer	Dec 06 '24	Option Exercise	0.84	50,000	42,000	186,380	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 05 '24	Option Exercise	0.84	49,640	41,698	186,020	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 04 '24	Option Exercise	0.84	45,000	37,800	181,380	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 06 '24	Sale	14.23	50,000	711,615	136,380	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 05 '24	Sale	14.13	49,640	701,642	136,380	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 04 '24	Sale	13.95	45,000	627,944	136,380	Dec 06 07:15 PM
Chakma Justin	Officer	Dec 06 '24	Proposed Sale	14.00	50,000	700,000		Dec 06 05:30 PM
Chakma Justin	Officer	Dec 05 '24	Proposed Sale	13.32	49,640	661,205		Dec 05 05:06 PM
Chakma Justin	Chief Business Officer	Dec 02 '24	Option Exercise	0.84	45,000	37,800	181,380	Dec 04 09:45 PM
Chakma Justin	Chief Business Officer	Dec 03 '24	Option Exercise	0.84	45,000	37,800	181,380	Dec 04 09:45 PM
Chakma Justin	Chief Business Officer	Dec 02 '24	Sale	13.67	45,000	615,218	136,380	Dec 04 09:45 PM
Chakma Justin	Chief Business Officer	Dec 03 '24	Sale	13.19	45,000	593,402	136,380	Dec 04 09:45 PM
Shawver Laura	Director	Dec 03 '24	Option Exercise	2.60	87,984	229,010	298,330	Dec 04 09:40 PM
Shawver Laura	Director	Dec 02 '24	Option Exercise	1.27	97,244	123,500	307,590	Dec 04 09:40 PM
Shawver Laura	Director	Dec 04 '24	Option Exercise	3.15	14,772	46,532	225,118	Dec 04 09:40 PM
Shawver Laura	Director	Dec 02 '24	Sale	13.56	97,244	1,318,745	210,346	Dec 04 09:40 PM
Shawver Laura	Director	Dec 03 '24	Sale	13.26	87,984	1,166,897	210,346	Dec 04 09:40 PM
Shawver Laura	Director	Dec 04 '24	Sale	13.75	14,772	203,109	210,346	Dec 04 09:40 PM
Karas Eric	Chief Commercial Officer	Dec 04 '24	Option Exercise	1.50	6,283	9,424	11,976	Dec 04 09:40 PM
Karas Eric	Chief Commercial Officer	Dec 02 '24	Option Exercise	1.50	3,717	5,576	9,410	Dec 04 09:40 PM
Karas Eric	Chief Commercial Officer	Dec 04 '24	Sale	14.00	6,283	87,962	5,693	Dec 04 09:40 PM
Karas Eric	Chief Commercial Officer	Dec 02 '24	Sale	14.11	3,717	52,461	5,693	Dec 04 09:40 PM
ERIC KARAS	Officer	Dec 04 '24	Proposed Sale	14.00	6,283	87,962		Dec 04 05:46 PM
Chakma Justin	Officer	Dec 04 '24	Proposed Sale	14.51	45,000	652,950		Dec 04 05:15 PM
Chakma Justin	Officer	Dec 03 '24	Proposed Sale	13.00	45,000	585,000		Dec 03 05:25 PM
Chakma Justin	Officer	Dec 02 '24	Proposed Sale	14.51	45,000	652,950		Dec 02 07:01 PM
Shawver Laura	Director	Dec 02 '24	Proposed Sale	13.56	200,000	2,713,000		Dec 02 06:22 PM
ERIC KARAS	Officer	Dec 02 '24	Proposed Sale	14.11	3,717	52,461		Dec 02 04:42 PM
Chakma Justin	Chief Business Officer	Nov 26 '24	Sale	14.05	42,186	592,570	161,380	Nov 27 04:11 PM
Chakma Justin	Chief Business Officer	Nov 25 '24	Sale	14.00	32,814	459,422	203,566	Nov 27 04:11 PM
Chakma Justin	Chief Business Officer	Nov 27 '24	Sale	14.39	25,000	359,750	136,380	Nov 27 04:11 PM
Lowenthal Richard E	PRESIDENT AND CEO	Nov 19 '24	Sale	13.95	100,000	1,394,960	1,198,499	Nov 21 04:30 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Nov 19 '24	Sale	13.95	100,000	1,394,960	1,198,499	Nov 21 04:30 PM
Chakma Justin	Officer	Nov 15 '24	Proposed Sale	17.30	236,380	4,089,374		Nov 15 03:21 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Nov 12 '24	Sale	16.85	100,000	1,684,642	1,248,499	Nov 14 04:30 PM
Lowenthal Richard E	PRESIDENT AND CEO	Nov 12 '24	Sale	16.85	100,000	1,684,642	1,248,499	Nov 14 04:30 PM
Flynn James E	10% Owner	Nov 11 '24	Sale	18.04	528,456	9,534,642	5,274,735	Nov 13 08:16 PM
Flynn James E	10% Owner	Nov 12 '24	Sale	17.49	34,814	609,064	5,257,328	Nov 13 08:16 PM
Scott Kathleen D.	Chief Financial Officer	Oct 16 '24	Option Exercise	1.50	12,500	18,750	17,449	Oct 17 04:30 PM
Scott Kathleen D.	Chief Financial Officer	Oct 16 '24	Sale	16.00	12,500	200,000	4,949	Oct 17 04:30 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Oct 15 '24	Sale	14.88	100,000	1,487,595	1,298,499	Oct 17 04:30 PM
Lowenthal Richard E	PRESIDENT AND CEO	Oct 15 '24	Sale	14.88	100,000	1,487,595	1,298,499	Oct 17 04:30 PM
KATHLEEN D SCOTT	Officer	Oct 16 '24	Proposed Sale	16.00	12,500	200,000		Oct 16 04:01 PM
Tanimoto Sarina	Officer	Oct 15 '24	Proposed Sale	14.00	300,000	4,200,000		Oct 15 11:28 AM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Oct 08 '24	Sale	13.83	100,000	1,382,775	1,346,494	Oct 10 04:28 PM
Lowenthal Richard E	PRESIDENT AND CEO	Oct 08 '24	Sale	13.83	100,000	1,382,775	1,346,494	Oct 10 04:27 PM
Karas Eric	Chief Commercial Officer	Sep 18 '24	Option Exercise	1.50	10,000	15,000	15,693	Sep 19 04:30 PM
Karas Eric	Chief Commercial Officer	Sep 18 '24	Sale	14.00	10,000	140,000	5,693	Sep 19 04:30 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Sep 17 '24	Sale	12.93	100,000	1,293,205	1,398,499	Sep 19 04:29 PM
Lowenthal Richard E	PRESIDENT AND CEO	Sep 17 '24	Sale	12.93	100,000	1,293,205	1,398,499	Sep 19 04:26 PM
ERIC KARAS	Officer	Sep 18 '24	Proposed Sale	14.00	10,000	140,000		Sep 18 04:06 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Sep 10 '24	Sale	11.50	100,000	1,149,775	1,396,494	Sep 12 04:25 PM
Lowenthal Richard E	PRESIDENT AND CEO	Sep 10 '24	Sale	11.50	100,000	1,149,775	1,396,494	Sep 12 04:24 PM
Lowenthal Richard E	Officer	Sep 10 '24	Proposed Sale	11.36	300,000	3,408,000		Sep 10 10:31 AM
Thompson Peter A.	Director	Aug 26 '24	Sale	13.00	83,695	1,088,035	0	Aug 28 04:30 PM
ORBIMED ADVISORS LLC	Director	Aug 26 '24	Sale	13.00	83,695	1,088,035	0	Aug 28 04:26 PM
Thompson Peter A.	Director	Aug 21 '24	Sale	13.56	407,700	5,526,601	544,677	Aug 23 06:41 PM
Thompson Peter A.	Director	Aug 22 '24	Sale	12.94	391,482	5,065,777	153,195	Aug 23 06:41 PM
Thompson Peter A.	Director	Aug 23 '24	Sale	13.03	69,500	905,585	83,695	Aug 23 06:41 PM
ORBIMED ADVISORS LLC	Director	Aug 21 '24	Sale	13.56	407,700	5,526,601	544,677	Aug 23 06:38 PM
ORBIMED ADVISORS LLC	Director	Aug 22 '24	Sale	12.94	391,482	5,065,777	153,195	Aug 23 06:38 PM
ORBIMED ADVISORS LLC	Director	Aug 23 '24	Sale	13.03	69,500	905,585	83,695	Aug 23 06:38 PM
Dorsey Brian	Chief Operating Officer	Aug 20 '24	Option Exercise	0.64	50,000	32,000	56,024	Aug 21 06:51 PM
Dorsey Brian	Chief Operating Officer	Aug 20 '24	Sale	15.00	50,000	750,000	6,024	Aug 21 06:51 PM
Karas Eric	Chief Commercial Officer	Aug 19 '24	Option Exercise	1.50	10,000	15,000	15,693	Aug 21 06:51 PM
Karas Eric	Chief Commercial Officer	Aug 19 '24	Sale	14.00	10,000	140,000	5,693	Aug 21 06:51 PM
Scott Kathleen D.	Chief Financial Officer	Aug 20 '24	Option Exercise	1.50	12,500	18,750	25,699	Aug 21 06:49 PM
Scott Kathleen D.	Chief Financial Officer	Aug 20 '24	Sale	16.00	12,500	200,000	13,199	Aug 21 06:49 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Aug 20 '24	Sale	15.03	100,000	1,502,587	1,497,447	Aug 21 06:48 PM
Lowenthal Richard E	PRESIDENT AND CEO	Aug 20 '24	Sale	15.03	100,000	1,502,587	1,497,447	Aug 21 06:47 PM
OrbiMed Partners Master Fund L	Shareholder	Aug 21 '24	Proposed Sale	14.89	952,377	14,180,894		Aug 21 06:43 PM
KATHLEEN D SCOTT	Officer	Aug 20 '24	Proposed Sale	16.00	12,500	200,000		Aug 20 04:18 PM
BRIAN T DORSEY	Officer	Aug 20 '24	Proposed Sale	15.00	50,000	750,000		Aug 20 04:05 PM
ERIC KARAS	Officer	Aug 19 '24	Proposed Sale	14.00	10,000	140,000		Aug 19 04:17 PM
Dorsey Brian	Chief Operating Officer	Aug 13 '24	Option Exercise	0.64	30,000	19,200	36,024	Aug 15 04:30 PM
Dorsey Brian	Chief Operating Officer	Aug 13 '24	Sale	13.00	30,000	390,000	6,024	Aug 15 04:30 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Aug 13 '24	Sale	12.48	100,000	1,247,555	1,446,494	Aug 15 04:30 PM
Lowenthal Richard E	PRESIDENT AND CEO	Aug 13 '24	Sale	12.48	100,000	1,247,555	1,446,494	Aug 15 04:30 PM
BRIAN T DORSEY	Officer	Aug 13 '24	Proposed Sale	13.00	30,000	390,000		Aug 13 05:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SPRY

ARS Pharmaceuticals Inc

Upgrade your FINVIZ experience